Pharma BD Deal Intelligence
Nurofen, Strepsils and Clearasil became durable pillars of Reckitt's Health franchise, though a high-profile Australian mislabeling scandal (2015-16) tarnished the Nurofen brand along the way.
Full analysis, sources & comparables →Reckitt outbid GSK and Bayer to win BHI for £1.9B; CEO Bart Becht said the deal would 'substantially strengthen' Reckitt's global position in healthcare and…
Reckitt would leverage its distribution network to push Nurofen, Strepsils and Clearasil into new channels and geographies; Boots CEO Richard Baker indicated…
Commission clearance decision: the operation does not create serious impediments to effective competition within the common market, permitting the Reckitt…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
OTC consumer health (Nurofen, Strepsils, Clearasil); GBP 1.93B
Nurofen, Strepsils and Clearasil became durable pillars of Reckitt's Health franchise, though a high-profile Australian mislabeling scandal (2015-16) tarnished the Nurofen brand along the way.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Reckitt Benckiser plc / Boots Healthcare International (this deal) | 2006 | $3.4B | 82 |
| Reckitt Benckiser plc / Adams Respiratory Therapeutics Inc. | 2007 | $2.3B | 82 |
| Reckitt Benckiser plc / Boots Healthcare International | 2005 | $3.4B | 78 |
| Reckitt Benckiser plc / Schiff Nutrition International, Inc. | 2012 | $1.4B | 67 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Crucell N.V. / Berna Biotech AG | 2006 | $450M | 85 |
| Lonza Group AG / Cambrex Bioproducts and Biopharma businesses | 2006 | $460M | 83 |